# EDGAR Filing Document

**Accession Number:** 0001293971
**File Stem:** 0001193125-23-000263
**Filing Date:** 2023-1
**Character Count:** 5059
**Document Hash:** 6f2a543d06227ca6135d8bdf4a2d2b02
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-000263.hdr.sgml**: 20230103

**ACCESSION NUMBER**: 0001193125-23-000263

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230103

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230103

**DATE AS OF CHANGE**: 20230103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** bluebird bio, Inc.
- **CENTRAL INDEX KEY:** 0001293971
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35966
- **FILM NUMBER:** 23500251

**BUSINESS ADDRESS:**
- **STREET 1:** 455 GRAND UNION BOULEVARD
- **CITY:** SOMERVILLE
- **STATE:** MA
- **ZIP:** 02145
- **BUSINESS PHONE:** 339-499-9300

**MAIL ADDRESS:**
- **STREET 1:** 455 GRAND UNION BOULEVARD
- **CITY:** SOMERVILLE
- **STATE:** MA
- **ZIP:** 02145

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Genetix Pharmaceuticals Inc
- **DATE OF NAME CHANGE:** 20040616

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of The Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): January 3, 2023

------

## bluebird bio, Inc.

#### (Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-35966** | **13-3680878** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **455 Grand Union Boulevard** |  |
| **Somerville, MA** | **02145** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

(339) 499-9300

#### (Registrant's telephone number, including area code)

#### Not Applicable

#### (Former name or former address, if changed since last report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common stock, $0.01 par value per share | BLUE | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.**  |

---

On January 3, 2023, bluebird bio, Inc. (the "Company") announced that Joseph Vittiglio, JD, has been appointed Chief Business and Legal Officer of the Company. Mr. Vittiglio brings more than 20 years of experience in the biopharmaceutical industry, with expertise in licensing, collaborations and mergers and acquisitions, financial transactions, U.S. Food and Drug Administration regulations, compliance, manufacturing, and quality operations for organizations at all stages of development.

Mr. Vittiglio joined the Company from Finch Therapeutics Group, Inc. ("Finch"), where he previously served as Chief Business and Legal Officer. Prior to joining Finch, he was the General Counsel and Chief Business Officer for AMAG Pharmaceuticals, Inc., where he led the company's legal and business development initiatives, including oversight of the successful sale of the company to private equity investors, multiple out-licensing and partnership collaborations, and multiple therapeutic product launches.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | bluebird bio, Inc. | bluebird bio, Inc. |
| Date: January 3, 2023 | By: | /s/ Andrew Obenshain |
|  | Name: | Andrew Obenshain |
|  | Title: | President and Chief Executive Officer |

---